ADMA BIOLOGICS, INC. Current Assets
ADMA BIOLOGICS, INC. (ADMA) had Current Assets of $528.20 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AssetsCurrent · last filed 2026-08-05
- 2026-06-30: Assets, Current $528.20M.
- 2026-03-31: Assets, Current $511.17M.
- 2025-12-31: Assets, Current $466.51M.
- 2025-09-30: Assets, Current $402.65M.
| Period end | Assets, Current | Assets, Current as first filed |
|---|---|---|
| 2026-06-30 | $528.20M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $511.17M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $466.51M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $402.65M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $399.56M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $351.81M 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $331.41M 10-K · filed 2026-02-25 | |
| 2024-09-30 | $318.19M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $303.69M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $276.42M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $257.01M 10-K · filed 2025-03-18 | |
| 2023-09-30 | $273.70M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $266.24M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $264.09M 10-Q · filed 2023-05-10 | |
| 2022-12-31 | $270.40M 10-K · filed 2024-02-28 | $270.40M 10-K · filed 2023-03-23 |
| 2022-09-30 | $224.09M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $222.77M 10-Q · filed 2022-08-10 | |
| 2022-03-31 | $239.80M 10-Q · filed 2022-05-11 | |
| 2021-12-31 | $208.73M 10-K · filed 2023-03-23 | |
| 2021-09-30 | $174.79M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $171.36M 10-Q · filed 2021-08-11 | |
| 2021-03-31 | $177.28M 10-Q · filed 2021-05-12 | |
| 2020-12-31 | $153.74M 10-K · filed 2022-03-24 | |
| 2020-09-30 | $139.55M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $142.99M 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $165.49M 10-Q · filed 2020-05-06 | |
| 2019-12-31 | $85.82M 10-K · filed 2021-03-25 | |
| 2019-09-30 | $97.32M 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $103.89M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $38.33M 10-Q · filed 2019-05-08 | |
| 2018-12-31 | $44.53M 10-K · filed 2020-03-13 | |
| 2018-09-30 | $62.50M 10-Q · filed 2018-11-09 | |
| 2018-06-30 | $73.63M 10-Q · filed 2018-08-10 | |
| 2018-03-31 | $46.42M 10-Q · filed 2018-05-14 | |
| 2017-12-31 | $62.34M 10-K · filed 2019-03-13 | $63.17M 10-K · filed 2018-03-29 |
| 2017-09-30 | $31.44M 10-Q · filed 2017-11-03 | |
| 2017-06-30 | $44.27M 10-Q · filed 2017-08-11 | |
| 2017-03-31 | $15.68M 10-Q · filed 2017-05-12 | |
| 2016-12-31 | $21.66M 10-K · filed 2018-03-29 | |
| 2016-09-30 | $25.36M 10-Q · filed 2016-11-10 | |
| 2016-06-30 | $29.49M 10-Q · filed 2016-08-12 | |
| 2016-03-31 | $17.36M 10-Q · filed 2016-05-13 | |
| 2015-12-31 | $21.29M 10-K · filed 2017-02-24 | |
| 2015-09-30 | $25.24M 10-Q · filed 2015-11-10 | |
| 2015-06-30 | $27.13M 10-Q · filed 2015-08-11 | |
| 2015-03-31 | $30.98M 10-Q · filed 2015-05-12 | |
| 2014-12-31 | $24.09M 10-K · filed 2016-03-23 | |
| 2014-09-30 | $22.57M 10-Q · filed 2014-11-10 | |
| 2014-06-30 | $26.49M 10-Q · filed 2014-08-11 | |
| 2014-03-31 | $30.79M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | $31.05M 10-K · filed 2015-03-09 | |
| 2013-09-30 | $7.14M 10-Q · filed 2013-11-12 | |
| 2013-06-30 | $9.17M 10-Q · filed 2013-08-12 | |
| 2013-03-31 | $12.31M 10-Q · filed 2013-05-14 | |
| 2012-12-31 | $13.95M 10-K · filed 2014-03-28 | |
| 2012-09-30 | $11.98M 10-Q · filed 2012-11-13 | |
| 2012-06-30 | $14.62M 10-Q · filed 2012-08-14 | |
| 2012-03-31 | $15.84M 10-Q · filed 2012-05-15 | |
| 2011-12-31 | $1.29M 10-K · filed 2013-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |